Metrion Biosciences Restricted (Metrion), the specialist ion channel CRO and drug discovery firm, at present introduced that it has secured £3.5m in new fairness financing, together with £2.5m from lead investor Maven Capital Companions (Maven) and £1 million from current investor, Gresham Home Ventures (Gresham Home).
The funding might be used to additional increase Metrion’s laboratories in Cambridge, UK, spend money on specialist tools and improve the Firm’s world advertising and marketing actions.
Metrion Biosciences additionally introduced a collection of board adjustments. Dr David Milroy has joined the board as Maven’s investor director and Steve Carle has changed Maya Ward as Gresham’s board consultant. On the identical time, Dr Marc Rogers, Dr Barry Kenny and Mark Keogh have retired as non-executive administrators of the Firm.
Dr Keith McCullagh, Chairman, Metrion Biosciences, mentioned: “I’m happy to welcome Maven as a brand new investor in Metrion. Andy Southan, Metrion’s CEO, and I are delighted that David Milroy, an skilled scientist and enterprise investor, will be a part of the board as Maven’s investor director. We additionally welcome Steve Carle to the board and thank Maya Ward for her assist of the spherical on behalf of Gresham. Lastly, we wish to thank Barry Kenny, Mark Keogh and Marc Rogers as they step down from the board, for his or her skilled recommendation and unwavering dedication to the Firm over a few years.”
Maven is a number one non-public fairness home centered on the supply of versatile funding for top development companies, and is likely one of the most lively SME traders within the UK.
David Milroy, Accomplice at Maven, mentioned: “The Metrion group are extremely regarded within the drug discovery business and are ideally positioned to capitalise on an growing understanding of ion channel biology and the ensuing heightened curiosity in therapeutics focusing on these channels. Maven has a robust monitor report of backing life science companies comparable to BioAscent, one other CRO, which has carried out very strongly because the Maven VCTs invested in 2018. I’m very a lot trying ahead to working with Andy and his group and to drawing on Maven’s expertise with comparable life science companies and plenty of different SMEs to assist scale this thrilling enterprise.”
Gresham Home is a development fairness investor specialising in software program and digitally pushed companies within the healthcare, client and providers sectors.
Maya Ward, funding director at Gresham Home Ventures, mentioned: “Because the timelines, price and complexity of taking a drug to market proceed to rise, we see growing demand for knowledgeable, specialist suppliers comparable to Metrion to help the biopharma business in navigating these challenges. The administration group’s deep perception into ion channels and specialist electrophysiology tools ensures Metrion is properly positioned to make the most of the sizeable market alternative. We look ahead to supporting the enterprise in its subsequent part of development.”
